8.23

0.12% 0.010

After Hours: 8.50 0.27 +3.28%

Ocular Therapeutix Inc (OCUL)

Overview News Price History Option Chain Financials Why OCUL Down? Discussions Forecast

Ocular Therapeutix Inc stock is traded at $8.23, with a volume of 2.03M. It is up +0.12% in the last 24 hours and down -14.80% over the past month. Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Previous Close:

$8.22

Open:

$8.23

24h Volume:

2.03M

Relative Volume:

0.48

Market Cap:

$1.80B

Revenue:

$52.04M

Net Income/Loss:

$-290.50M

P/E Ratio:

-7.762

EPS:

-1.0603

Net Cash Flow:

$-216.89M

1W Performance:

-10.15%

1M Performance:

-14.80%

6M Performance:

-32.76%

1Y Performance:

+14.07%

1-Day Range:

$8.1193

$8.36

1-Week Range:

$7.86

$9.245

52-Week Range:

$6.2301

$16.44

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Name

Ocular Therapeutix Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

781-357-4000

Address

14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA

Employee

325

Twitter

@OCUTX

Next Earnings Date

2026-05-05

Latest SEC Filings

OCUL's Discussions on Twitter

Compare OCUL vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCUL Ocular Therapeutix Inc	8.23	1.80B	52.04M	-290.50M	-216.89M	-1.0603
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-15-25	Initiated	Chardan Capital Markets	Buy
Apr-08-25	Initiated	William Blair	Outperform
Mar-18-25	Initiated	RBC Capital Mkts	Outperform
Mar-11-25	Initiated	Needham	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jun-20-24	Upgrade	TD Cowen	Hold → Buy
May-31-24	Resumed	Piper Sandler	Overweight
Feb-09-24	Initiated	BofA Securities	Buy
Apr-21-23	Initiated	Robert W. Baird	Outperform
Aug-10-22	Resumed	Berenberg	Buy
Aug-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-28-20	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-17-20	Initiated	Berenberg	Buy
Nov-13-20	Reiterated	Raymond James	Strong Buy
Aug-10-20	Reiterated	H.C. Wainwright	Buy
Mar-03-20	Upgrade	Raymond James	Outperform → Strong Buy
May-21-19	Downgrade	Cowen	Outperform → Market Perform
May-21-19	Reiterated	H.C. Wainwright	Buy
May-21-19	Downgrade	Raymond James	Strong Buy → Outperform
Dec-03-18	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-18	Initiated	Raymond James	Strong Buy
Sep-07-18	Initiated	Piper Jaffray	Overweight
Oct-24-17	Initiated	Guggenheim	Buy
Jul-26-17	Initiated	H.C. Wainwright	Buy
Jul-12-17	Reiterated	Cantor Fitzgerald	Overweight
Jun-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-10-17	Initiated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	RBC Capital Mkts	Outperform
Aug-11-16	Initiated	JMP Securities	Mkt Outperform
Feb-17-16	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-23-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-13-15	Initiated	Morgan Stanley	Overweight

View All

Ocular Therapeutix Inc Stock (OCUL) Latest News

May 24, 2026

Q3 2025 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus

May 24, 2026

Q2 2025 Ocular Therapeutix Inc Earnings Call Transcript - GuruFocus

May 24, 2026

Ocular Therapeutix Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus

May 24, 2026

May 22, 2026

OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill

May 22, 2026

May 20, 2026

Selling Ocular Therapeutix Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Moomoo

May 20, 2026

May 19, 2026

Can Ocular Therapeutix's (OCUL) Rising Losses on Flat Revenue Still Support Its R&D Ambitions? - simplywall.st

May 19, 2026

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - The Globe and Mail

May 19, 2026

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors - The Motley Fool

May 19, 2026

May 17, 2026

Why (OCUL) Price Action Is Critical for Tactical Trading - Stock Traders Daily

May 17, 2026

May 15, 2026

[SCHEDULE 13G/A] OCULAR THERAPEUTIX, INC Amended Passive Investment Disclosure - Stock Titan

May 15, 2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 15, 2026

New HR boss at Ocular Therapeutix lands 75,000 stock options, 25,000 RSUs - Stock Titan

May 15, 2026

May 13, 2026

Dole posts downbeat Q1 earnings, joins Ocular Therapeutix and other big stocks moving lower in Monday's pre-market session - MSN

May 13, 2026

Neuropathic Ocular Pain Therapeutics Market Size (7MM) - openPR.com

May 13, 2026